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This article contains experimental data examining the propensity
of neuronal ELAVL proteins to become isoaspartylated. The data are
related to the article “Isoaspartylation appears to trigger small cell
lung cancer-associated autoimmunity against neuronal protein
ELAVL4” (M.A. Pulido, M.K. DerHartunian, Z. Qin, E.M. Chung, D.S.
Kang, A.W. Woodham, J.A. Tsou, R. Klooster, O. Akbari, L. Wang, W.
M. Kast, S.V. Liu, J.J.G.M. Verschuuren, D.W. Aswad, I.A. Laird-Off-
ringa, 2016) [1], in which it was reported that the N-terminal
region of recombinant human ELAVL4 protein, incubated under
physiological conditions, acquires a type of highly immunogenic
protein damage. Here, we present Western blot analysis data
generated by using an afﬁnity-puriﬁed polyclonal rabbit antibody
(raised against an N-terminal ELAVL4 isoaspartyl-converted pep-
tide) to probe recombinant protein fragments of the other three
members of the ELAVL family: the highly homologous neuronal
ELAVL2 (HuB) and ELAVL3 (HuC), and the much less homologous
ubiquitously expressed ELAVL1 (HuR).
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.jneuroim.2016.09.002
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Value of the data
 The data encourages the investigation of isoaspartylation of other neuronal autoantigens.
 The data encourages the investigation of the oligomerization of autoantigens that might be prone
to isoaspartylation and allows comparison to other antigens.
 The data supports the generation of additional anti-isoaspartyl antisera by investigators, including
antisera to other neuronal SCLC auto-antigens.1. Data
The data shown consists of two parts. First, we provide the alignment of the N-terminal amino
acid sequences of ELAVL proteins, indicating regions of homology between the proteins and a peptide
used to generate a rabbit anti-isoaspartyl-ELAVL4 serum [1]. Secondly, we show Western blots doc-
umenting the reactivity of the afﬁnity-puriﬁed rabbit antiserum with recombinant human ELAVL2,
ELAVL3, ELAVL4, and ELAVL1 polypeptides (consisting of the N-terminal parts of the proteins,
including the ﬁrst RNA recognition motif).
) Amino acid sequence alignments of neuronal ELAVL proteins (ELAVL2-4) and the ubiquitously-
expressed ELAVL1 protein indicate any regions of homology with the peptide used to generate the
rabbit anti-isoaspartyl-ELAVL4 antiserum. The peptide sequence is underlined, amino acids
identical with the peptide sequence are highlighted in yellow and conserved substitutions are
highlighted in gray, with N for D substitutions noted in green. Canonical isoaspartylation sites (N or
D followed by S, G or H) are bolded. The N-terminal portion of the RNA recognition motif (RRM)
domain is marked by the black box. ELAVL1 was included as a negative control because it has little
homology to the peptide used to generate the anti-isoaspartyl-ELAVL4 serum.
) Western blot analysis of N-terminal regions of ELAVL proteins incubated under isoaspartyl-inducing
conditions for 0, 1, 3 or 7 days (top panel). We have previously shown that the ELAVL4 aa 1–117
fragment, similar to the N-terminal fragment used to broadly characterize the ELAVL immune
epitopes in numerous published studies (reviewed in [2]), becomes highly reactive with the
afﬁnity-puriﬁed anti-isoaspartyl-ELAVL4 rabbit antisera, and that both the monomer and oligomers
that form during isoaspartyl conversion show reactivity to the sera [1]. Oligomerization is a known
consequence of isoaspartylation [3–6]. Just like ELAVL4, ELAVL2 and 3 acquire cross-reactivity with
the anti-isoAsp-ELAVL4 antiserum during the isoaspartyl conversion (Fig. 1B, top panel). Reactivity
with ELAVL2 closely resembles that of ELAVL4, while ELAVL3 only shows cross-reactivity in the
dimer form. This may be because the homology between the N-terminal regions of ELAVL4 and
Fig. 1. Alignment of ELAVL family members and examination of cross-reactivity with afﬁnity-puriﬁed anti-isoaspartyl-ELAVL4
rabbit antiserum.
M.A. Pulido et al. / Data in Brief 9 (2016) 1052–10551054ELAVL2 is higher than that of ELAVL3. The dimer proteins may exhibit alternative epitopes or show
altered binding kinetics favoring antibody binding to the dimer, which may explain why reactivity
with the ELAVL3 dimer is seen while reactivity with the monomer is not observed. As the
Coomassie gel shows (Fig. 1B, bottom panel), the oligomers (which are resistant to denaturation)
M.A. Pulido et al. / Data in Brief 9 (2016) 1052–1055 1055are present in modest amounts but appear to be unusually reactive. This ﬁgure is related to
Figure 2 in Pulido et al. [1].2. Experimental design, materials and methods
Recombinant human ELAVL2 (amino acids (aa) 1–117), ELAVL3 (aa 1–117), ELAVL4 (aa 1–117), and
ELAVL1 (aa 1–98) polypeptides with C-terminal hexahistidine tags were produced in E. coli BL21(DE3)
(New England Biolabs, Ipswich, MA, USA). The protein fragments contain the whole N-terminal RNA
recognition motif (RRM) and amino acids N-terminal to it. Recombinant proteins were incubated under
isoaspartyl-inducing conditions for 0, 1, 3 and 7 days (50 mM K-HEPES pH 7.4, 1 mM EGTA, 0.02% w/v
sodium azide, 5% w/v glycerol at 37 °C as described [1]). 1 μg of each recombinant protein sample per
lane was denatured for 10 min at 100 °C in reducing loading buffer (60 mM Tris–HCl pH 6.8, 2% SDS,
0.01% bromophenol blue, 5% 2-mercaptoethanol, 10% glycerol) and run on polyacrylamide gel
electrophoresis-SDS gels (14%), transferred to Immun-Blot PVDF membranes (Bio-Rad, Hercules, CA,
USA) and probed with an afﬁnity-puriﬁed polyclonal rabbit antiserum [1] raised against CTSNTS-
isoAsp-GPSSNNR-amide peptide carrying an isoaspartyl moiety at the central asparagine. The afﬁnity-
puriﬁed anti-isoaspartyl-ELAVL4 antiserumwas used at 1:250 dilution in TBST (20 mM Tris/HCl, pH 8.0,
150 mM NaCl, 0.05% Tween 20) with 5% milk, washed in TBST and probed with a secondary goat anti-
rabbit IgG HRP conjugate (at 1:20,000 in TBST with 3% milk) ( # sc-2004, Santa Cruz, CA, USA) followed
by visualization with a chemiluminescent HRP substrate kit (Millipore, Danvers, MA, USA) on a Bio-Rad
Fluor-STM MultiImager (BioRad, Hercules, CA, USA) according to the manufacturers’ instructions.Acknowledgements
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